Aptus Pharma Management
Management criteria checks 1/4
Aptus Pharma's CEO is Ghanshyam Pansuriya, appointed in Jan 2025, has a tenure of less than a year. total yearly compensation is ₹1.11M, comprised of 23.1% salary and 76.9% bonuses, including company stock and options. directly owns 5.1% of the company’s shares, worth ₹46.20M. The average tenure of the management team and the board of directors is 0.9 years and 1.7 years respectively.
Key information
Ghanshyam Pansuriya
Chief executive officer
₹1.1m
Total compensation
| CEO salary percentage | 23.15% |
| CEO tenure | less than a year |
| CEO ownership | 5.1% |
| Management average tenure | less than a year |
| Board average tenure | 1.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | ₹1m | ₹256k | ₹31m |
| Mar 31 2024 | ₹816k | n/a | ₹9m |
| Mar 31 2023 | ₹542k | n/a | ₹2m |
| Mar 31 2022 | ₹4m | n/a | ₹1m |
Compensation vs Market: Ghanshyam's total compensation ($USD12.47K) is below average for companies of similar size in the Indian market ($USD46.08K).
Compensation vs Earnings: Ghanshyam's compensation has increased by more than 20% in the past year.
CEO
Ghanshyam Pansuriya (42 yo)
Mr. Ghanshyam Vinubhai Pansuriya is Chief Executive Officer of Aptus Pharma Limited from January 1, 2025 and he joined the Company as a Director on August 12, 2010, but later resigned from the directorship...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | less than a year | ₹1.11m | 5.1% ₹ 46.2m | |
| Chief Financial Officer | less than a year | ₹856.00k | 11.3% ₹ 102.3m | |
| Company Secretary & Compliance Officer | less than a year | ₹546.08k | no data | |
| MD & Director | 1.8yrs | ₹840.00k | 11.3% ₹ 102.3m |
Experienced Management: 544529's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Director | 15.3yrs | ₹840.00k | 11.3% ₹ 102.3m | |
| Independent Director | less than a year | no data | no data | |
| Non-Executive Director | 1.8yrs | no data | 8.38% ₹ 75.9m | |
| Independent Director | less than a year | no data | no data | |
| Non-Executive Director | 1.8yrs | no data | 8.38% ₹ 75.9m | |
| Non-Executive Director | 1.5yrs | no data | no data |
Experienced Board: 544529's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/04 17:51 |
| End of Day Share Price | 2025/11/04 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aptus Pharma Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.